Bristol Myers Squibb (BMS; NYSE: BMY) has announced that a late-stage study for its KRAS inhibitor, Krazati (adagrasib), has successfully met its primary endpoint in patients with previously treated locally advanced or metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC). The study demonstrated that Krazati increased median progression-free survival (PFS) from 3.8 months to 5.5 months compared to chemotherapy, improved the overall response rate (ORR) from 9% to 32%, and extended the median duration of response (mDOR) from 5.4 months to 8.3 months.
Among patients with central nervous system (CNS) metastases, Krazati showed significant improvement in the intracranial response rate, increasing it from 11% to 24%. The safety profile of the drug remained consistent with previous reports, with no new safety signals observed.
Krazati is also under development for other solid tumors, including colorectal cancer (CRC) and pancreatic cancer, indicating its potential in treating a broader range of oncological conditions.- Flcube.com
